CLRLB.png
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
January 04, 2022 08:30 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
CLRLB.png
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
December 13, 2021 08:30 ET | Cellectar Biosciences
Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma Mean ORR of 45.5%, CBR of 72.7% and DCR of 100% and the subset of quad/penta drug refractory patients...
CLRLB.png
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
December 08, 2021 08:30 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
CLRLB.png
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
November 16, 2021 08:30 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
CLRLB.png
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
November 08, 2021 08:30 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted...
CLRLB.png
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
November 02, 2021 08:30 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted...
CLRLB.png
Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies
October 25, 2021 09:00 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted...
CLRLB.png
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer
September 22, 2021 08:30 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
CLRLB.png
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021 16:01 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
CLRLB.png
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia
August 18, 2021 08:30 ET | Cellectar Biosciences
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...